Olanzapine-associated diabetes mellitus

Pharmacotherapy

Volumn 22, Issue 7, 2002, Pages 841-852

  Koller, Elizabeth A ^a   Doraiswamy, P Murali ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; OLANZAPINE; PIRENZEPINE; ALLOXAN; ANTIDEPRESSANT AGENT; BENZATROPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PAROXETINE; PENTAMIDINE; QUETIAPINE; RISPERIDONE; SERTRALINE; STEROID; STREPTOZOCIN; THIAZIDE DIURETIC AGENT; THYROID HORMONE; VALPROIC ACID; VENLAFAXINE;

BLOOD; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; RETROSPECTIVE STUDY; REVIEW; ADOLESCENT; ADULT; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDLINE; METABOLIC ACIDOSIS; ONSET AGE; PROVOCATION TEST;

BENZODIAZEPINES; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; PIRENZEPINE; RETROSPECTIVE STUDIES; HUMAN;

EID: 0035990397     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.11.841.33629     Document Type: Review

References (64)

1. Atypical antipsychotics. I. Pharmacology, pharmacokinetics, and efficacy
2. Psychosis due to neurological conditions
3. Use of olanzapine in non-psychotic psychiatric disorders
4. Olanzapine in the treatment of delirium
5. Pediatric uses of atypical antipsychotics
6. Olanzapine-induced glucose dysregulation
7. Olanzapine-induced diabetes mellitus
8. Het hyperglykemisch dehydratiesyndroom
9. Olanzapine-induced acute pancreatitis
10. Hyperglycemia associated with olanzapine
11. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
12. Diabetic ketoacidosis with olanzapine treatment
13. Increasing insulin dose for olanzapine-related diabetes
14. Atypical antipsychotic drugs and hyperglycemia in adolescents
15. Olanzapine-induced ketoacidosis with diabetes mellitus
16. Diabetes mellitus associated with atypical antipsychotic medications: New case report and review of the literature
17. Hyperglycemia and olanzapine
18. Diabetes as a result of atypical anti-psychotic drugs: A report of three cases
19. Olanzapine-induced hyperglycemic nonketonic coma
20. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: Case report and review of literature
21. Diabetic ketoacidosis associated with olanzapine in an adolescent patient
22. Olanzapine, new onset diabetes and suicidal insulin overdose
23. Hyperglykamie and ketoazidose unter olanzapin
24. New-onset diabetes and ketoacidosis with atypical antipsychotics
25. Novel antipsychotics and new-onset diabetes
26. Hyperinsulinemia in cirrhotic patients infected with hepatitis C virus
27. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon
28. Weight gain during treatment with valproate
29. Altered ovarian function and cardiovascular risk factors in valproate-treated women
30. Bodyweight gain and anticonvulsants: A comparative review
31. The effect of valproate on blood metabolite concentrations in spontaneously diabetic, ketoacidotic, BB/E Wistar rats
32. Non-ketotic hyperosmolar coma with hyperglycemia: Clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria, and the effects of therapy in 37 cases
33. Clinical and metabolic characteristics of hyperosmolar non-ketotic coma
34. Prevalence and incidence of non-insulin dependent diabetes
35. Clozapine-associated diabetes
36. Schizophrenia and other psychotic disorders
37. Gender and bipolar illness
38. Gender differences in mood disorders: A literature review
39. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat
40. Neuroendocrine effects during haloperidol therapy in chronic schizophrenia
41. Incidence of adverse drug events and potential adverse drug events: Implications for prevention
42. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse events
43. Attitudinal survey of voluntary reporting of adverse drug reactions
44. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age
45. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: Risk and predictors of under-reporting
46. Reporting of adverse drug reactions by hospital doctors and the response to intervention
47. Physician knowledge, attitudes, and behavior related to reporting adverse drug events
48. Hospital pharmacy compliance with JCAHO standards and ASHP guidelines for reporting adverse drug reactions
49. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance
50. Impaired glucose tolerance and abnormal movements in patients with schizophrenia
51. Severe hyperglycemia associated with high doses of clozapine
52. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
53. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
54. Diabetic ketoacidosis associated with risperidone treatment?
55. Olanzapine-related hyperglycemia in a nondiabetic woman
56. Olanzapine-induced diabetic ketoacidosis
57. Olanzapine-induced neutropenia in patients with history of clozapine treatment: Two case reports from a state psychiatric institution